ACADIA Pharmaceuticals develops small molecule drugs to address central nervous system disorders like Parkinson's disease psychosis and Rett syndrome. Its pipeline includes NUPLAZID for the treatment of hallucinations and delusions and pimavanserin for Alzheimer's disease psychosis and negative symptoms of schizophrenia, among others. The company was founded in 1993 and is based in San Diego, California.